Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126053415 | 12605341 | 5 | F | 20160718 | 20160830 | 20160729 | 20160905 | PER | PHEH2016US018570 | NOVARTIS | 80.41 | YR | F | Y | 0.00000 | 20160903 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126053415 | 12605341 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 13.3 MG, QD (RIVASTIGMINE BASE 27 MG) | 6543.79785 | MG | N | 4345A, 4405B | 22083 | 13.3 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | ||
| 126053415 | 12605341 | 2 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | UNK | 6543.79785 | MG | N | 22083 | TRANS-THERAPEUTIC-SYSTEM |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126053415 | 12605341 | 1 | Dementia with Lewy bodies |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126053415 | 12605341 | Drug effect decreased | |
| 126053415 | 12605341 | Product adhesion issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126053415 | 12605341 | 1 | 20150315 | 0 | ||
| 126053415 | 12605341 | 2 | 20160722 | 0 |